Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
Savaj S et al. | Irreversible Lesions of Tacrolimus-induced Posterior Reversible Leukoencephalopathy Syndrome. | 2017 | Iran J Kidney Dis | pmid:29190599 |
Kabat-Koperska J et al. | Birth defects in juvenile Wistar rats after exposure to immunosuppressive drugs during pregnancy. | 2017 | Histol. Histopathol. | pmid:27097725 |
Cheung AY et al. | Probable Donor-Derived Cytomegalovirus Disease After Keratolimbal Allograft Transplantation. | 2017 | Cornea | pmid:28614157 |
Weir MR et al. | Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. | 2017 | Transplantation | pmid:26950714 |
Nakamura Y et al. | Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation. | 2017 | Intern. Med. | pmid:28502936 |
Shen CL et al. | Tacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft Rejection. | 2017 | Sci Rep | pmid:28512328 |
Sanghavi K et al. | Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. | 2017 | Pharmacogenomics J. | pmid:26667830 |
Størset E et al. | Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. | 2017 | Br J Clin Pharmacol | pmid:28374426 |
Ikeda K et al. | Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. | 2017 | Rheumatol. Int. | pmid:28283734 |
Morita M et al. | The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report. | 2017 | Odontology | pmid:27368962 |
Shimizu S et al. | Reduction of FR900525 using an S-(2-aminoethyl) l-cysteine-resistant mutant. | 2017 | J. Biosci. Bioeng. | pmid:28185832 |
Hashemizadeh Z et al. | Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28923870 |
Piotti G et al. | Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. | 2017 | J. Nephrol. | pmid:27206763 |
Ma TK et al. | Therapeutic drug monitoring of once-daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient. | 2017 | Nephrology (Carlton) | pmid:28064453 |
Percy C et al. | Impact of Acute Infection Requiring Hospitalization on Tacrolimus Blood Levels in Kidney Transplant Recipients. | 2017 | Transplant. Proc. | pmid:29149962 |
de Menezes AF et al. | Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review. | 2017 | Pediatr Dermatol | pmid:27878842 |
Ganschow R et al. | Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. | 2017 | Pediatr Transplant | pmid:28714558 |
Hasegawa J et al. | Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients. | 2017 | Int. J. Infect. Dis. | pmid:28986314 |